Heterocyclic amides as kinase inhibitors
Disclosed are compounds having the formula: wherein R 1 , R 2 , and R 3 are as defined herein, and methods of making and using the same.
1. A method of alleviating or mitigating a RIP1 kinase-mediated disease or disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound according to Formula (I):
wherein:
R 1 is (C 1 -C 4 )alkoxy-CH 2 -, phenyl(C 1 -C 4 )alkoxy-CH 2 -, or a substituted or unsubstituted (C 2 -C 4 )alkynyl, (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )cycloalkyl-(C 1 -C 4 )alkyl-group, or a substituted or unsubstituted 5-6 membered heterocycloalkyl group further optionally substituted by halogen or (C 1 -C 4 )alkyl,
wherein said substituted (C 3 -C 6 )cycloalkyl, (C 3 -C 6 )cycloalkyl-alkyl-, or 5-6 membered heterocycloalkyl group is substituted by 1, 2 or 3 substituents independently selected from hydroxyl, (benzyloxy)carbonyl)amino, cyano, halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkyl-CO-, cyano(C 1 -C 4 )alkyl-CO-, (C 1 -C 4 )alkoxy-(C 1 -C 4 )alkyl-CO-, (C 1 -C 4 )alkoxy-CO-, (C 1 -C 4 )alkylNHCO-, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)NCO-, halo(C 1 -C 4 )alkyl-CO-, optionally substituted (C 3 -C 6 )cycloalkyl-CO-, optionally substituted (C 3 -C 6 )cycloalkyl-(C 1 -C 4 )alkyl-CO-, optionally substituted phenyl-CO-, optionally substituted phenyl-SO 2 -, optionally substituted phenyl(C 1 -C 4 )alkyl-CO-, optionally substituted 5-6 membered heteroaryl-CO-, and optionally substituted 9-10 membered heteroaryl-CO-,
wherein said optionally substituted (C 3 -C 6 )cycloalkyl-CO-, optionally substituted (C 3 -C 6 )cycloalkyl-(C 1 -C 4 )alkyl-CO-, optionally substituted phenyl-CO-, optionally substituted phenyl-SO 2 -,optionally substituted phenyl(C 1 -C 4 )alkyl-CO-, optionally substituted 5-6 membered heteroaryl-CO-, or optionally substituted 9-10 membered heteroaryl-CO-is optionally substituted by 1 or 2 substituents independently selected from halogen, cyano, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkyl-CO-, halo(C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl-CO-, (C 3 -C 6 )cycloalkyl and 5-6 membered heterocycloalkyl; or
said substituted (C 2 -C 4 )alkynyl, (C 3 -C 6 )cycloalkyl or 5-6 membered heterocycloalkyl group is substituted by an optionally substituted phenyl, 5-6 membered heteroaryl or 9-membered heteroaryl group,
wherein said phenyl, 5-6 membered heteroaryl or 9-membered heteroaryl group is optionally substituted by 1 or 2 substituents independently selected from halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkyl-CO-, halo(C 1 -C 4 )alkyl, and halo(C 1 -C 4 )alkyl-CO-;
R 2 is a substituted or unsubstituted phenyl, (C 3 -C 6 )cycloalkyl, 5-6 membered oxygen-containing heterocycloalkyl, 5-6 membered heteroaryl, 9-membered heteroaryl, 9-10 membered carbocyclic-aryl, or 9-10 membered heterocyclic-aryl group,
wherein said substituted phenyl, (C 3 -C 6 )cycloalkyl, 5-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 9-membered heteroaryl, 9-10 membered carbocyclic-aryl, or 9-10 membered heterocyclic-aryl group is substituted by 1, 2 or 3 substituents independently selected from halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, and cyano;
R 3 is H or halogen;
or pharmaceutically acceptable salt thereof,
provided the compound is not:
cyclohexyl(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone; and
wherein the RIP 1 kinase-mediated disease or disorder is selected from Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
2. A method of alleviating or mitigating a RIP1 kinase-mediated disease or disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of a compound according to Formula (I) which is (S)-1-(4-(5(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperidin-1-yl)ethenone
or a pharmaceutically acceptable salt thereof; and
wherein the RIP1 kinase-mediated disease or disorder is selected from Alzheimer's disease, Parkinson's disease, and multiple sclerosis.